Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a short-acting sulfonamide with uses similar to sulfamethoxazole. Together with pyrimethamine it is used in the treatment of toxoplasmosis. Oral administration every 4 - 6 hours.
Since the last update we have not found published data on its excretion in breastmilk.
Sulphamides are excreted in small amounts in breast milk: 6 to 94 micrograms/ml, 1.6% of the total dose. (Briggs 2015)
Reports of adverse effects are rare (Briggs 2015). Avoid in suspected glucose-6-phosphate dehydrogenase deficiency.
Due to the greater toxicity than that of other antimicrobials and their high acquired resistance, the use of sulfonamides is currently very scarce. (Pérez 2003)